Last checked at 5 Jun 2017 18:00
5 June 2017 |
Advanced Medical Solutions Group plc
("AMS", the "Company" or the "Group")
Director/PDMR and PCA Shareholding
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), a leading developer and manufacturer of advanced products for the global surgical and advanced wound care markets, announces that it was notified on 31 May 2017 that Chris Meredith, who is a Director and PDMR, following the successful achievement of certain performance criteria, had exercised the following options from certain share incentive schemes, as outlined below. Chris Meredith, also sold Ordinary Shares of 5p each on 31 May 2017 at a share price of 277.554p per Ordinary Share in part to cover the tax payable on this exercise.
As a result of these transactions Chris Meredith's beneficial interest in the Company has increased from 1,192,508 shares to 1,384,841 shares.
Long Term Incentive Plan (LTIP)
Director | No. of LTIPs prior to exercise | LTIPs exercised | Ordinary Shares sold | Ordinary shares retained | LTIPs after exercise |
Chris Meredith, Chief Executive Officer | 1,078,007 | 445,814 | 271,049 | 174,765 | 632,193 |
Deferred Share Bonus Plan (DSB)
Director | No. of DSBs prior to exercise | DSBs exercised | Ordinary Shares sold | DSBs after exercise |
Chris Meredith, Chief Executive Officer | 32,686 | 17,568 | Nil | 15,118 |
Overall holding
Director | Holding prior to exercise | Number of shares exercised | Number of shares sold | Sale price (p) | Resultant holding | % of issued share capital |
Chris Meredith, Chief Executive Officer | 1,192,508 | 463,382 | 271,409 | 277.554p | 1.384,841 | 0.65% |
The Company further announces that it was notified on 31 May 2017 that Mary Tavener, who is a Director and PDMR, following the successful achievement of certain performance criteria, had exercised the following options from certain share incentive schemes, as outlined below. Mary Tavener, also sold Ordinary Shares of 5p each on 31 May 2017 as detailed below at a share price of 277.554p per Ordinary Share in part to cover the tax payable on this exercise.
As a result of these transactions Mary Tavener's beneficial interest in the Company has increased from 1,829,813 shares to 1,890,647 shares.
Long Term Incentive Plan (LTIP)
Director | No. of LTIPs prior to exercise | LTIPs exercised | Ordinary Shares sold | Ordinary shares retained | LTIPs after exercise |
Mary Tavener, Chief Financial Officer | 675,961 | 199,319 | 148,423 | 50,896 | 476,642 |
Deferred Share Bonus Plan (DSB)
Director | No. of DSBs prior to exercise | DSBs exercised | Ordinary Shares sold | DSBs after exercise |
Mary Tavener, Chief Financial Officer | 19,203 | 9,938 | Nil | 9,265 |
Overall holding
Director | Holding prior to exercise | Number of shares exercised | Number of shares sold | Sale price (p) | Resultant holding | % of issued share capital |
Mary Tavener, Chief Financial Officer | 1,829,813 | 209,257 | 148,423 | 277.554p | 1,890,647 | 0.89% |
The Company further announces that it was notified on 31 May 2017 that Eddie Johnson, who is a Senior Manager and PDMR, had exercised 6,243 Ordinary Shares of 5p from the Deferred Share Bonus Plan and sold 9,704 shares as detailed below at a share price of 277.554p per Ordinary Share.
Following these transactions the beneficial ownership of Eddie Johnson is as follows:
Deferred Share Bonus Plan (DSB)
PDMR | No. of DSBs prior to exercise | DSBs exercised | Ordinary Shares sold | DSBs after exercise |
Eddie Johnson | 59,237 | 6,243 | 6,243 | 52,994 |
Overall holding
PDMR | Holding prior to exercise | Number of shares sold | Sale price (p) | Resultant holding | % of issued share capital |
Eddie Johnson | 52,195 | 3,461 | 277.554p | 48,734 | 0.023% |
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name: Chris Meredith | ||||
2. | Reason for the notification | ||||
a) | Position/status: Director/PDMR | ||||
b) | Initial notification/Amendment: Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name: Advanced Medical Solutions Group plc | ||||
b) | LEI: 213800HJP6OWOSZI1L74 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||
b) | Nature of the transactions: · Exercise of 445,814 shares from the Long Term Incentive Plan · Exercise of 17,568 shares from the Deferred Share Bonus Plan · Sale of 271,049 Ordinary Shares of 5p | ||||
c) | Price(s) and volume(s): Sale of shares:
| ||||
d) | Aggregated information: (Relates to those shares sold only) Aggregated volume: 271,049 Aggregated price: £2.77554 | ||||
e) | Date of the transaction: 31/05/2017 | ||||
f) | Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name: Mary Tavener | ||||
2. | Reason for the notification | ||||
a) | Position/status: Director/PDMR | ||||
b) | Initial notification/Amendment: Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name: Advanced Medical Solutions Group plc | ||||
b) | LEI: 213800HJP6OWOSZI1L74 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||
b) | Nature of the transactions: · Exercise of 199,319 shares from the Long Term Incentive Plan · Exercise of 9,938 shares from the Deferred Share Bonus Plan · Sale of 148,423 Ordinary Shares of 5p | ||||
c) | Price(s) and volume(s): Sale of shares:
| ||||
d) | Aggregated information: (Relates to those shares sold only) Aggregated volume: 148,423 Aggregated price: £2.77554 | ||||
e) | Date of the transaction: 31/05/2017 | ||||
f) | Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. | Details of the person discharging managerial responsibilities/person closely associated | ||||
a) | Name: Eddie Johnson | ||||
2. | Reason for the notification | ||||
a) | Position/status: Senior Manager/PDMR | ||||
b) | Initial notification/Amendment: Initial Notification | ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name: Advanced Medical Solutions Group plc | ||||
b) | LEI: 213800HJP6OWOSZI1L74 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
a) | Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 | ||||
b) | Nature of the transaction: · Exercise of 6.243 shares from the Deferred Share Bonus Plan · Sale of 9,704 Ordinary Shares of 5p | ||||
c) | Price(s) and volume(s): Sale of shares:
| ||||
d) | Aggregated information: (Relates to those shares sold only) Aggregated volume: 9,704 Aggregated price: £2.77554 | ||||
e) | Date of the transaction: 31/05/2017 | ||||
f) | Place of the transaction: London Stock Exchange, AIM Market (XLON) |
-End -
For further information, please visit www.admedsol.com or contact:
Advanced Medical Solutions Group plc | Tel: +44 (0) 1606 545508 |
Chris Meredith, Chief Executive Officer Mary Tavener, Chief Financial Officer | |
Consilium Strategic Communications | Tel: +44 (0) 20 3709 5700 |
Mary-Jane Elliott / Jonathan Birt / Matthew Neal / Hendrik Thys | AMS@consilium-comms.com |
Investec Bank plc(NOMAD & Broker) | Tel: +44 (0) 20 7597 5970 |
Daniel Adams / Patrick Robb |
About Advanced Medical Solutions Group plc - see www.admedsol.com
AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical and advanced wound care markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of wound care products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it sells under white label as well as its own brand ActivHeal®, and surgical tissue adhesives, sutures and haemostats, which markets under its own brands; LiquiBand® and RESORBA®.
AMS's products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in more than 70 countries via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Company has 600 employees. For more information, please see www.admedsol.com.